{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-09-03T03:29:18.310633+00:00","company":{"ticker":"NPHC","cik":1119643,"company_name":"NUTRA PHARMA CORP"},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"auditor_change","fact_key":"9a62faefe32419458c1b62460c9d0dcc701d321d","cik":1119643,"ticker":"NPHC","company_name":"NUTRA PHARMA CORP","filed_at":"2025-09-03T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Astra Audit & Advisory","disagreement_text":null,"effective_date":"2024-12-18","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"NUTRA PHARMA CORP engaged Astra Audit & Advisory as its auditor.","evidence_excerpt":"On December 18, 2024, the Board approved the engagement of Astra Audit & Advisory (“AA”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-026384","anchor_url":"https://secwatch.observer/filing/0001641172-25-026384#claim-9a62faefe32419458c1b62460c9d0dcc701d321d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1119643/000164117225026384/0001641172-25-026384-index.htm"},{"fact_type":"auditor_change","fact_key":"708b1464fe858b408e47aaf1b0bba74390f7f46a","cik":1119643,"ticker":"NPHC","company_name":"NUTRA PHARMA CORP","filed_at":"2025-09-03T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"Marcum LLP","disagreement_text":null,"effective_date":"2024-03-27","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Astra Audit & Advisory"},"claim":"Marcum LLP resigned as auditor of NUTRA PHARMA CORP.","evidence_excerpt":"On March 27, 2024, the Audit Committee of the Board of Directors (the “Committee”) of Nutra Pharma Corp. (the “Company”) received a letter indicating the resignation of Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-026384","anchor_url":"https://secwatch.observer/filing/0001641172-25-026384#claim-708b1464fe858b408e47aaf1b0bba74390f7f46a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1119643/000164117225026384/0001641172-25-026384-index.htm"},{"fact_type":"executive_change","fact_key":"3a5fa0f056","cik":1119643,"ticker":"NPHC","company_name":"NUTRA PHARMA CORP","filed_at":"2024-03-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-20","interim":false,"role":"Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Michael Flax was appointed as Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer at NUTRA PHARMA CORP.","evidence_excerpt":"On March 20, 2024, our Board of Directors unanimously approved of the appointment of Michael Flax, DDS as our Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-010998","anchor_url":"https://secwatch.observer/filing/0001493152-24-010998#claim-3a5fa0f056","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1119643/000149315224010998/0001493152-24-010998-index.htm"},{"fact_type":"executive_change","fact_key":"07cd6f8e2d","cik":1119643,"ticker":"NPHC","company_name":"NUTRA PHARMA CORP","filed_at":"2024-03-22T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"for_cause_or_dispute","effective_date":"2024-03-19","interim":false,"role":"Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer","role_category":"ceo","successor_name":"Michael Flax","successor_named":true},"claim":"Rik J. Deitsch resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer at NUTRA PHARMA CORP.","evidence_excerpt":"On March 19, 2024, Mr. Deitsch submitted a letter of resignation to our Board of Directors and thereby resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer of Nutra Pharma Corp., effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-010998","anchor_url":"https://secwatch.observer/filing/0001493152-24-010998#claim-07cd6f8e2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1119643/000149315224010998/0001493152-24-010998-index.htm"}]}